Driven by natural ingredient demand and infection prevention technologies, the skin repair sector faces challenges in product efficacy and consumer trust. Gender-neutral solutions emerge as a key ...

According to a Phase 3 clinical trial (INTEGUMENT-PED) roflumilast cream 0.05% is effective and safe for children aged 2-5 ...

Orismilast may be an effective and safe novel treatment option for adult patients with moderate to severe atopic dermatitis.

Arcutis Biotherapeutics (ARQT) announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ ...

The FDA has cleared an Investigational New Drug Application for Zabalafin Hydrogel, a multi-target therapy for mild to ...

Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills ...

Jason B. Pieper, DVM, MS, DACVD: The causes for otitis externa. I mean, definitely the number one is going to be allergies, which then usually are going to be food allergies and atopic dermatitis or ...

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to ...

Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

The AADA continues to increase awareness among employers of the impact skin conditions have on employee health, productivity, ...